Skip to main content
NIHPA Author Manuscripts logoLink to NIHPA Author Manuscripts
. Author manuscript; available in PMC: 2016 Oct 16.
Published in final edited form as: Org Lett. 2015 Sep 30;17(20):4933–4935. doi: 10.1021/acs.orglett.5b02389

Small molecules in the cone snail arsenal

Jorge LB Neves , Zhenjian Lin §, Julita S Imperial , Agostinho Antunes , Vitor Vasconcelos , Bal-domero M Olivera ⊥,*, Eric W Schmidt ⊥,§,*
PMCID: PMC4845746  NIHMSID: NIHMS779663  PMID: 26421741

Abstract

Cone snails are renowned for producing peptide-based venoms, the conopeptides and conotoxins, to capture their prey animals. Here, we show that small molecules also contribute to the activity of the venoms. A novel guanine derivative, genuanine, causes paralysis in mice and is found in the venoms of at least two cone snail species. Genuanine contains unprecedented features for a natural nucleic acid.

Graphical abstract

graphic file with name nihms779663f4.jpg


Marine mollusks of the genus Conus produce bioactive peptides that are used in medicine.1 Each snail synthesizes an array of different peptides, each of which targets a specific receptor or ion channel subtype, often with exquisite selectivity. The combination of these peptides, referred to as a “cabal”, creates a unique response in prey animals, incapacitating prey and enabling consumption by the cone snail.2 Although cone snails eat fish, polychaete worms, or other mollusks, because of the striking conservation of many ion channels and receptors across higher animals, the peptides are often highly selective to human proteins as well.

Because of these properties, cone snail research has focused on venom peptides, with good reason. Recently, we found potent neuroactivity in a venom fraction containing small molecules. Here, we describe the discovery of a novel guanine derivative, genuanine, which induces paralysis in mice. Given the extensive previous chemical characterization in cones, even in one of the species described below, it is remarkable that this bioactive guanine derivative with novel modifications of the purine ring was never characterized prior to the present study. Natural small molecule derivatives of nucleic acids, such as cytosine arabinoside, often have novel biological activity, sometimes with important biomedical applications.

Conus genuanus was collected in São Vicente, Cape Verde. C. genuanus belongs to a small number of cones with a pigmented venom duct, prompting us to search for small molecule pigments, which have not yet been characterized in cones. The red pigment is asymmetrically distributed when the venom is in situ in the venom duct of the snail. Dry venom collected from the red portion of the venom duct was extracted, providing a mixture of small molecules that was neuroactive when injected into mice. Careful examination of the venom components indicated several compounds, including unstable pigments that are under investigation. However, one of these, genuanine, was stable and was solely responsible for the paralytic activity in mice observed in the small-molecule fraction.

Genuanine was isolated as a colorless solid (1 mg). Solubility issues and the small amount of available material limited the NMR analysis. The 1H NMR spectrum showed only two methylene triplets (∂ 3.00, 4.43 ppm, t, J = 7.5 Hz) and one methyl singlet (∂ 2.74 ppm, s). An HSQC spectrum indicated chemical shifts consistent with adjacency of the methylenes to nitrogen and the methyl to an aromatic carbon. Indeed, a 15N-HMBC spectrum revealed connectivity to two nitrogen units, as well as the proximity of the methylene and methyl groups. A 13C-HMBC experiment indicated the substructure as shown in Figure 1a.

Figure 1.

Figure 1

Structure of genuanine. A) Key HMBC data used to determine the right ring substructure. Red arrows: 15N-HMBC; black arrows: 13C-HMBC. B) Structure of genuanine.

Despite insufficient NMR data, the molecular mass (m/z = 238.0935) and a characteristic UV signature led us to speculate that the genuanine was a derivative of guanine (Figure 1b). Genuanine was synthesized from guanine in two steps. The synthetic material initially appeared on the basis of 1H NMR spectroscopy to be different from the natural genuanine. However, upon mixing the natural and synthetic material together, it became apparent that the two are identical (Figure S1 3.11 and 3.12), but that chemical shifts are extremely sensitive to slight changes in conditions (Figure S2). Combination of synthetic and natural genuanine in 35% DCl enabled measurement of a 13C spectrum, providing further evidence of the structure as shown. Thus, the structure of genuanine was simultaneously elucidated and confirmed.

Compound 1 exhibited profound activity at doses as low as 40 nmol per mouse, in which the mouse was paralyzed in all 4 limbs for >2 h. However, best activity was obtained with fresh samples, and activity decreased with storage time (see Supporting Information for a complete table of all conditions and doses tested). This activity mimicked the potent paralytic activity found in the venom extract. The reason for this loss of activity over time has yet to be elucidated, but it was reproducible with both natural and synthetic 1.

Initial attempts to improve synthetic yield also led to an array of regioisomers of genuanine, compounds 24 (Figure 2), for which no activity was detected (Table S1), suggesting a possible structure-activity relationship underlying neuroactivity.. Other nucleic acid analogs with neuroactivity have previously been described. For example, a series of 8-oxoisoguanines from sponges inhibit GABAergic transmission in mice, while a sea anemone adenosine derivative caissarone is an adenosine receptor antagonist.4 In the synthetic arena, guanine derivatives have been synthesized as purinergic receptor agonists and antagonists that act centrally,5 among many other activities. It is highly speculative to connect any of these previous results to our observed activity here, but they provide further confidence that nucleic acids can affect paralysis and the CNS. It is noteworthy that genuanine is present in sufficient quantity to exert the same effect in the crude venom. Thus, we propose that 1 is an active constituent cone snail prey-capturing arsenal, and not just a passive ingredient in the venom duct.

Figure 2.

Figure 2

Synthesis of genuanine (top)3 and synthetic isomers used in biological assays (bottom).

Venom peptides vary greatly between cone snail species,1b so we sought to determine whether genuanine was widespread or restricted to C. genuanus. At random, we selected 9 additional cone snails collected from various locations in the Pacific Ocean for chemical analysis. We also selected C. imperialis from Oahu, Hawaii. While C. imperialis is not closely related to C. genuanus, it shares in common a pigmented venom duct and to the best of our knowledge is the only other cone with a similar venom duct, having 2 regions of different colors. Only C. genuanus and C. imperialis contained genuanine. Other venom duct extracts were rich in nucleic acids, but these were the primary metabolites guanine and hypoxanthine.

Recently, it has been shown that Conus geographus venom peptides vary in different regions of the venom duct.6 Similarly, in C. genuanus, the red (distal) and yellow (proximal) venom duct products are very different (Figures 3 and S6). While the proximal venom duct contains largely peptidic, high-molecular weight components, the distal venom duct is dominated by low-molecular weight materials, of which genuanine 1 is the major stable metabolite.

Figure 3.

Figure 3

Venom components from C. genuanus. HPLC-UV traces show that the distal and proximal venom ducts contain quite different components (top). Enumeration of major peaks in HPLC-MS spectra show that, in contrast to the proximal duct the distal duct is dominated by small molecules (bottom).

Genuanine belongs to a rare family of C-8 methylated nucleic acid derivatives. Nucleosides are methylated at C-8 by radical alkylators, such as procarbazine.7 In nature, a C-8 methylated adenosine derivative is known as a component of bacteria ribosomal RNA;8 its biosynthesis utilizes radical SAM enzymes.9 To the best of our knowledge, these compounds were not known from eukaryotes, nor was the methylated guanine or guanosine known in nature. Genuanine is also modified by propionate on N-9, which is a previously unknown modification of nucleic acids. Speculatively, this group could possibly also be added from methionine via a radical SAM enzyme, among other possible routes, possibly based upon tRNA metabolism. Alternatively, in other mollusks pigmented organs are associated with oxidative / radical metabolism10 consistent with C-8 modification. A large family of nucleic acid analogs from marine animals. Most recently, several nucleosides from a sponge were produced by bacteria cultivated from the same sponge.11 Both cone snails and their associated bacteria are known to produce compounds,12 but determination of the ultimate source of genuanine awaits experiment.

The finding of paralytic small molecules as venom components in cone snails was unanticipated. To the best of our knowledge, only one previous report documents a small molecule: serotonin was found in small amounts in the venom duct of C. imperialis.13 Thus, it appears that small molecules are important and previously unrecognized contributors to the toxicity of cone snail venoms.

Supplementary Material

Supporting material

Acknowledgments

This project was funded by NIH R01GM107557 to EWS, NIGMS P01GM048677 to BMO, NIH ICBG U01TW008163 to EWS and BMO, and UID/Multi/04423/2013, MARBIOTECH and NOVOMAR. We thank J. Cox of the Utah Mass Spectrometry and Proteomics Core for mass measurements reported in this study; and the Foundation for Science and Technology (FCT - SFRH/BD/51477/2011), Fundação Calouste Gulbenkian and University of Cape Verde (UniCV) for sample collection support.

Footnotes

ASSOCIATED CONTENT

Supporting Information

Supporting Information. Materials and methods, NMR and MS spectra. The Supporting Information is available free of charge on the ACS Publications website at DOI:.

Author Contributions

All authors have given approval to the final version of the manuscript.

The authors declare no competing financial interest.

REFERENCES

  • 1.(a) Brady RM, Baell JB, Norton RS. Mar. Drugs. 2013;11:2293. doi: 10.3390/md11072293. [DOI] [PMC free article] [PubMed] [Google Scholar]; (b) Robinson SD, Norton RS. Mar. Drugs. 2014;12:6058. doi: 10.3390/md12126058. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Jimenez EC, Shetty RP, Lirazan M, Rivier J, Walker C, Abogadie FC, Yoshikami D, Cruz LJ, Olivera BM. J. Neurochem. 2003;85:610. doi: 10.1046/j.1471-4159.2003.01685.x. [DOI] [PubMed] [Google Scholar]
  • 3.(a) Maeda M, Nushi K, Kawazoe Y. Tetrahedron. 1974;30:2677–2682. [Google Scholar]; (b) Vo DD, Staedel C, Zehnacker L, Benhida R, Darfeuille F, Duca M. ACS Chem. Biol. 2014;9:711. doi: 10.1021/cb400668h. [DOI] [PubMed] [Google Scholar]; (c) Kim Jin C, Kim M, Jung J, Lee J, Ree Brian J, Kim H, Kim Ik J, Kim Jung R, Ree MJ. Polym. Sci., Part A: Polymer Chemistry. 2015;53:1151. [Google Scholar]; (d) Cheng G, Wang M, Villalta Peter W, Hecht Stephen S. Chem. Res. Toxicol. 2010;V23:1089. doi: 10.1021/tx100062v. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.(a) Sakurada T, Gill MB, Frausto S, Noguchi K, Shimamoto K, Swanson GT, Sakai R. J. Med. Chem. 2010;53:6089. doi: 10.1021/jm100490m. [DOI] [PMC free article] [PubMed] [Google Scholar]; (b) Cooper RA, de Freitas JC, Porreca F, Eisenhour CM, Lukas R, Huxtable RJ. Toxicon. 1995;33:1025. doi: 10.1016/0041-0101(95)00047-p. [DOI] [PubMed] [Google Scholar]
  • 5.Matasi JJ, Brumfield S, Tulshian D, Czarnecki M, Greenlee W, Garlisi CG, Qiu H, Devito K, Chen SC, Sun Y, Bertorelli R, Geiss W, Le VD, Martn GS, Vellekoop SA, Haber J, Allard ML. Bioorg. Med. Chem. Lett. 2011;21:3805. doi: 10.1016/j.bmcl.2011.04.034. [DOI] [PubMed] [Google Scholar]
  • 6.Safavi-Hemami H, Hu H, Gorasia DG, Bandyopadhyay PK, Veith PD, Young ND, Reynolds EC, Yandell M, Olivera BM, Purcell AW. Mol. Cell. Proteom. 2014;13:938. doi: 10.1074/mcp.M113.031351. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Lemke TL, Williams DA, editors. Foye's Principles of Medicinal Chemistry. Baltimore: Lippincott Williams & Wilkins; 2012. [Google Scholar]
  • 8.Giessing AM, Jensen SS, Rasmussen A, Hansen LH, Gondela A, Long K, Vester B, Kirpekar F. RNA. 2009;15:327. doi: 10.1261/rna.1371409. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Grove TL, Benner JS, Radle MI, Ahlum JH, Landgraf BJ, Krebs C, Booker SJ. Science. 2011;332:604. doi: 10.1126/science.1200877. [DOI] [PubMed] [Google Scholar]
  • 10.Derby CD. Biol. Bull. 2007;213:274. doi: 10.2307/25066645. [DOI] [PubMed] [Google Scholar]
  • 11.Bertin MJ, Schwartz SL, Lee J, Korobeynikov A, Dorrestein PC, Gerwick L, Gerwick WH. J. Nat. Prod. 2015;78:493. doi: 10.1021/np5009762. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.(a) Hillyard DR, Olivera BM, Woodward S, Corpuz GP, Gray WR, Ramilo CA, Cruz LJ. Biochemistry. 1989;38:358. doi: 10.1021/bi00427a049. [DOI] [PubMed] [Google Scholar]; (b) Lin Z, Torres JP, Ammon MA, Marett L, Teichert RW, Reilly CA, Kwan JC, Hughen RW, Flores M, Tianero MD, Peraud O, Cox JE, Light AR, Villaraza AJ, Haygood MG, Concepcion GP, Olivera BM, Schmidt EW. Chem. Biol. 2013;20:73. doi: 10.1016/j.chembiol.2012.10.019. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.McIntosh JM, Foderaro TA, Li W, Ireland CM, Olivera BM. Toxicon. 1993;31:1561. doi: 10.1016/0041-0101(93)90340-o. [DOI] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Supporting material

RESOURCES